Adomeglivant (BioDeep_00000802606)
代谢物信息卡片
化学式: C32H36F3NO4 (555.2596292000001)
中文名称: 阿度格列凡
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)OC(CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O
InChI: InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10861
- PubChem: 91933867
- DrugBank: DB11704
- ChEMBL: CHEMBL3707351
- CAS: 1488363-78-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sofie Hædersdal, Asger Lund, Henrik Maagensen, Elisabeth Nielsen-Hannerup, Lærke S Gasbjerg, Mette M Rosenkilde, Julie L Forman, Gerrit van Hall, Jens J Holst, Filip K Knop, Tina Vilsbøll. The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes.
European journal of endocrinology.
2022 Jan; 186(2):207-221. doi:
10.1530/eje-21-0865. [PMID: 34863038] - Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens J Holst, Filip K Knop, Tina Vilsbøll. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Diabetes.
2020 12; 69(12):2619-2629. doi:
10.2337/db20-0369. [PMID: 33004472] - Cristina B Guzman, Xiaotian M Zhang, Rong Liu, Arie Regev, Sudha Shankar, Parag Garhyan, Sreekumar G Pillai, Christof Kazda, Naga Chalasani, Thomas A Hardy. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2017 11; 19(11):1521-1528. doi:
10.1111/dom.12958. [PMID: 28371155] - Christof M Kazda, Juan Frias, Irene Foga, Xuewei Cui, Cristina B Guzman, Parag Garhyan, Cory Heilmann, Jihui Anne Yang, Thomas A Hardy. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2017 08; 19(8):1071-1077. doi:
10.1111/dom.12904. [PMID: 28191913] - Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz, Mark A Deeg, David E Moller, Thomas A Hardy. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes care.
2016 Jul; 39(7):1241-9. doi:
10.2337/dc15-1643. [PMID: 26681715] - R P Kelly, P Garhyan, E Raddad, H Fu, C N Lim, M J Prince, J A Pinaire, M T Loh, M A Deeg. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.
Diabetes, obesity & metabolism.
2015 Apr; 17(4):414-22. doi:
10.1111/dom.12446. [PMID: 25656305]